Nervous System News and Research

Latest Nervous System News and Research

Regeneration of central nervous system axons can be achieved: Study

Scientists at the University of California, San Diego School of Medicine report that regeneration of central nervous system axons can be achieved in rats even when treatment delayed is more than a year after the original spinal cord injury.

29 Oct 2009

Brain cell transplants help replace degenerated neurons, finds Swiss research team

A Swiss research team has found that using an animal's own brain cells (autologous transplant) to replace degenerated neurons in select brain areas of donor primates with simulated but asymptomatic Parkinson's disease and previously in a motor cortex lesion model, provides a degree of brain protection and may be useful in repairing brain lesions and restoring function.

29 Oct 2009

Study links low maternal folate levels with attention-deficit/hyperactivity problems in children

It has long been suggested that healthy folate (the natural form of folic acid) levels in expectant mothers goes hand in hand with healthy nervous system development in their children. A study published in an upcoming issue of the Journal of Child Psychology and Psychiatry finds that low maternal folate levels is linked to the development of attention-deficit/hyperactivity problems in children at age seven to nine years.

29 Oct 2009

Clinical Data raises $47.4 million through public offering of shares

Clinical Data, Inc. today announced that it has raised gross proceeds of approximately $47.4 million through the public offering of 2,750,000 newly issued shares of its common stock at a price of $17.25 per share. All of the shares are being offered by Clinical Data, Inc.

28 Oct 2009

StemCells to raise $12.5 million

StemCells, Inc. announced today that it has entered into an agreement to raise approximately $12.5 million in gross proceeds through the sale of approximately 10 million shares of its common stock to selected institutional investors at a price of $1.25 per share. The investors will also receive warrants to purchase approximately four million shares of common stock at an exercise price of $1.50 per share.

28 Oct 2009

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study.

28 Oct 2009

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

Orexigen® Therapeutics, Inc. today announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trials of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity. These data expand on top-line results announced in July and complement findings from a panel discussion on Saturday where the Company presented data on Contrave patients who completed 56 weeks of therapy.

28 Oct 2009

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.

28 Oct 2009

Roche's high-throughput sequencing technology used for high-resolution HLA genotyping

A study published this month in the journal Tissue Antigens reports that researchers at Roche Molecular Systems in Pleasanton, CA have used high-throughput sequencing technology from 454 Life Sciences, a Roche Company, to carry out high-resolution human leukocyte antigen (HLA) genotyping in research samples.

27 Oct 2009

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Alkermes, Inc. today announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled study will assess the safety, tolerability and pharmacokinetic effects of a single oral administration of five doses of ALKS 37 in approximately 40 healthy volunteers.

27 Oct 2009

BioMarin Pharmaceutical acquires Huxley Pharmaceuticals

Rodman & Renshaw Capital Group, Inc. announced today that its affiliate, Aceras BioMedical LLC (Aceras), has sold Huxley Pharmaceuticals Inc. (Huxley), a portfolio company, to BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Huxley was established by Aceras in August 2008 with a focus on developing therapeutic products for rare diseases of the nervous system.

27 Oct 2009

New data from efficacy study of CIMZIA in Crohn's disease patients presented

New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.

27 Oct 2009

Deep brain stimulation: New treatment option for people with severe Tourette syndrome

Deep brain stimulation may be a safe and effective treatment for Tourette syndrome, according to research published in the October 27, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

27 Oct 2009

Diabetes decreases cognitive decline in people with Alzheimer's disease

New research published in the October 27, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology, suggests that those with both diseases actually have a slower rate of memory loss than people who had only Alzheimer's disease.

27 Oct 2009

New significant tool to improve the quality of care for patients with brain tumors released

While the nation is debating how best to reform healthcare, the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) announce a new significant tool to improve the quality of care for patients who suffer from brain tumors.

27 Oct 2009

Innovative approach to build a new drug to treat a number of CNS diseases

Working like an architect, Prof. Hagit Eldar-Finkelman of Tel Aviv University's Sackler School of Medicine is "building" a new drug, L803-MTS, to treat a number of central nervous system (CNS) diseases like Alzheimer's. In pre-clinical studies, it also shows promise against Parkinson's, Huntington's and diabetes.

27 Oct 2009

Cephalon, BDC sign option agreement

Cephalon, Inc. and BioAssets Development Corporation (BDC), a privately held biopharmaceutical company, today announced that the companies have signed an agreement that will provide Cephalon with an option to acquire BDC.

26 Oct 2009

Enzyme Mst3b is essential for regenerating damaged axons in live animal model, say researchers

Researchers at Children's Hospital Boston report that an enzyme known as Mst3b, previously identified in their lab, is essential for regenerating damaged axons (nerve fibers) in a live animal model, in both the peripheral and central nervous systems.

26 Oct 2009

Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave

Orexigen® ( )Therapeutics, Inc today announced new data from the COR-I, COR-II and COR-Diabetes trials for Contrave® (bupropion SR/ naltrexone SR) to expand on top-line results announced in July. Contrave is the first of the Company's two late stage candidates for the treatment of obesity.

26 Oct 2009

Study: High protein levels are associated with heart attack and not stroke

People with high levels of a protein called C-reactive protein (CRP), a marker for inflammation in the blood, may be at higher risk for heart attack and death but not stroke, according to a study published in the October 20, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

26 Oct 2009

Nervous System News and Research

Latest Nervous System News and Research

Regeneration of central nervous system axons can be achieved: Study

Brain cell transplants help replace degenerated neurons, finds Swiss research team

Study links low maternal folate levels with attention-deficit/hyperactivity problems in children

Clinical Data raises $47.4 million through public offering of shares

StemCells to raise $12.5 million

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Roche's high-throughput sequencing technology used for high-resolution HLA genotyping

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

BioMarin Pharmaceutical acquires Huxley Pharmaceuticals

New data from efficacy study of CIMZIA in Crohn's disease patients presented

Deep brain stimulation: New treatment option for people with severe Tourette syndrome

Diabetes decreases cognitive decline in people with Alzheimer's disease

New significant tool to improve the quality of care for patients with brain tumors released

Innovative approach to build a new drug to treat a number of CNS diseases

Cephalon, BDC sign option agreement

Enzyme Mst3b is essential for regenerating damaged axons in live animal model, say researchers

Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave

Study: High protein levels are associated with heart attack and not stroke

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Nervous System News and Research

Latest Nervous System News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in